The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: From obscure liver transporters to key determinants of hepatobiliary clearance

Xenobiotica

Volumn 42, Issue 1, 2012, Pages 28-45

  Fenner, Katherine S ^a   Jones, Hannah M ^a   Ullah, Mohammed ^a   Kempshall, Sarah ^a   Dickins, Maurice ^a   Lai, Yurong ^b   Morgan, Paul ^a   Barton, Hugh A ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Hepatic transport proteins; Hepatobiliary clearance and pharmacokinetics; OATPs

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CERIVASTATIN; CYCLOSPORIN; DRUG METABOLIZING ENZYME; FEXOFENADINE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOSARTAN; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 2; MYOTONIC DYSTROPHY PROTEIN KINASE; OLMESARTAN; ORGANIC ANION TRANSPORTER; PITAVASTATIN; PRAVASTATIN; REPAGLINIDE; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; TERAZOSIN; TERFENADINE; TORASEMIDE; UK 191005; UK 294315; UK 338003; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; BILE FLOW; CELL CULTURE; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TRANSPORT; GENETIC TRANSFECTION; HAY FEVER; HEPATOBILIARY SYSTEM; HUMAN; HYDROGEN BOND; LIVER CELL; LIVER CLEARANCE; LIVER PERFUSION; NONHUMAN; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVIEW;

EID: 82955168418     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.626464     Document Type: Review

References (152)

1. Abe K, Bridges AS, Brouwer KL. (2009). Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos 37:447-452.
2. Akamine Y, Miura M, Sunagawa S, Kagaya H, Yasui-Furukori N, Uno T. (2010). Infuence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica 40:782-789.
3. Amundsen R, Christensen H, Zabihyan B, Asberg A. (2010). Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 38:1499-1504.
4. Asberg A. (2003). Interactions between cyclosporin and lipid-lowering drugs: Implications for organ transplant recipients. Drugs 63:367-378. (Pubitemid 36259524)
5. Ayrton A, Morgan P. (2001). Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497. (Pubitemid 32826389)
6. Ayrton A, Morgan P. (2008). Role of transport proteins in drug discovery and development: A pharmaceutical perspective. Xenobiotica 38:676-708.
7. Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ. (2009). CYP2C8 activity recovers within 96 hours after gemfbrozil dosing: Estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos 37:2359-2366.
8. Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. (2000). Plasma concentrations of active simvastatin acid are increased by gemfbrozil. Clin Pharmacol Ter 68:122-129. (Pubitemid 30659167)
9. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. (2002). Gemfbrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ter 72:685-691. (Pubitemid 36021007)
10. Betts A, Atkinson F, Gardner I, Fox D, Webster R, Beaumont K, Morgan P. (2007). Impact of physicochemical and structural properties on the pharmacokinetics of a series of α1L-adrenoceptor antagonists. Drug Metab Dispos 35:1435-1445. (Pubitemid 47121786)
11. Bi Y, Kazolias D, Duignan DB. (2006). Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Met Disp 34:1658-1665. (Pubitemid 44285409)
12. Binet I, Wallnöfer A, Weber C, Jones R, Tiel G. (2000). Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int 57:224-231. (Pubitemid 30227769)
13. Borst P, de Wolf C, van de Wetering K. (2007). Multidrug resistance-associated proteins 3, 4, and 5. Pfugers Arch 453:661-673. (Pubitemid 46192537)
14. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR. (2011). Diferential efect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. doi:10.1038/tpj.2010.92.
15. Castell JV, Jover R, Martínez-Jiménez CP, Gómez-Lechón MJ. (2006). Hepatocyte cell lines: Teir use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2:183-212. (Pubitemid 46372364)
16. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA. (2005). Diferential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 33:537-546. (Pubitemid 40393197)
17. Choi MK, Jin QR, Choi YL, Ahn SH, Bae MA, Song IS. (2011). Inhibitory efects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: Considerations on drug-drug interactions. Biopharm Drug Dispos 32:175-184.
18. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ. (2005). Efect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ter 78:342-350.
19. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871. (Pubitemid 29347585)
20. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. (2007). Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766-1780. (Pubitemid 47481568)
21. Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG. (2008). Te efect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: Te contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18:424-433. (Pubitemid 351535943)
22. Dingemanse J, van Giersbergen PL. (2004). Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Phar-macokinet 43:1089-1115. (Pubitemid 40013178)
23. EMA DDI draft guidance. (2010). Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2010/05/WC500090112.pdf
24. Evers R, Chu XY. (2008). Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Mol Pharmacol 74:309-311.
25. Flynn CA, Hagenbuch BA, Read GA. (2010) Losartan is a substrate of organic anion transporting polypeptide 2B1 FASEB J. 24 (meeting abstract supplement) 758.2
26. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. (2010). Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38:981-987.
27. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. (2004). Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34:961-971. (Pubitemid 40070099)
28. Funk C. (2008). Te role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 4:363-379. (Pubitemid 351728512)
29. Furberg CD, Pitt B. (2001). Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2:205-207. (Pubitemid 33019612)
30. Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT. (1995). Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver. Xenobiotica 25:185-197.
31. Glavinas H, Méhn D, Jani M, Oosterhuis B, Herédi- Szabó K, Krajcsi P. (2008). Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin Drug Metab Toxicol 4:721-732. (Pubitemid 352003195)
32. Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T. (2001). AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ter 298:62-70. (Pubitemid 32574511)
33. Gui C, Hagenbuch B. (2008). Molecular determinants for substrate selectivity of OATP-1B3. FASEB J. 151:393-399.
34. Gui C, Hagenbuch B. (2010). Cloning/characterization of the canine organic anion transporting polypeptide 1b4 (Oatp1b4) and classifcation of the canine OATP/SLCO members. Comp Biochem Physiol C Toxicol Pharmacol 151:393-399.
35. Gui C, Obaidat A, Chaguturu R, Hagenbuch B. (2010). Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4:1-8.
36. Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S. (1999). Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant Proc 31:2163-2165. (Pubitemid 29376559)
37. Hagenbuch B, Meier PJ. (2004). Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classifcation as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pfugers Arch 447:653-665. (Pubitemid 38241451)
38. Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801.
39. Hamelin BA, Turgeon J. (1998). Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical efects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37. (Pubitemid 28094090)
40. Harrison A, Betts A, Fenner K, Beaumont K, Edgington A, Rofey S, Davis J, Comby P, Morgan P. (2004). Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fuorophenyl)-6,7-dimethoxy-2-4- (morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl quinoline in humans: Use of preclinical data to rationalize clinical observations. Drug Metab Dispos 32:197-204. (Pubitemid 38176936)
41. Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, Ijima H, Saito Y. (2003). Te drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ter Med 19:381-389.
42. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. (2004). Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ter 75:101-109. (Pubitemid 38130122)
43. Hinton LK, Galetin A, Houston JB. (2008). Multiple inhibition mechanisms and prediction of drug-drug interactions: Status of metabolism and transporter models as exemplifed by gemfbrozil-drug interactions. Pharm Res 25:1063-1074. (Pubitemid 351521103)
44. Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ter 311:139-146. (Pubitemid 39287793)
45. Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
46. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
47. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. (2009). Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
48. Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479. (Pubitemid 24167255)
49. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identifcation of a liver-specifc human organic anion transporting polypeptide and identifcation of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168.
50. Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, Inoue T, Okuyama A. (2001). Changes in lipid metabolism and efect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158:417-423. (Pubitemid 32913652)
51. Ieiri I, Higuchi S, Sugiyama Y. (2009). Genetic polymorphisms of uptake (OATP1B1, 1B3) and efux (MRP2, BCRP) transporters: Implications for inter-individual diferences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-729.
52. Igel M, Sudhop T, von Bergmann K. (2001). Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57:357-364. (Pubitemid 33787186)
53. Inoue M, Kinne R, Tran T, Arias IM. (1982). Taurocholate transport by rat liver sinusoidal membrane vesicles: Evidence of sodium cotransport. Hepatology 2:572-579. (Pubitemid 13173939)
54. International Transporter Consortium (2010). Membrane transporters in drug development. Nature Rev Drug Discov 9:215-236.
55. Ito K, Houston JB. (2005a). Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112. (Pubitemid 40558152)
56. Ito K, Hallifax D, Obach RS, Houston JB. (2005b). Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844. (Pubitemid 40686638)
57. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ter 82:541-547. (Pubitemid 47622520)
58. Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. (2001). A comparison of the efects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 29:282-288. (Pubitemid 32179528)
59. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, Sugiyama Y. (2006). Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109-1115.
60. Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, Roth W, Igarashi T, Sugiyama Y. (2008). Establishment of a set of double transfectants coexpressing organic anion transporting poly-peptide 1B3 and hepatic efux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 36:796-805. (Pubitemid 351468387)
61. Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Talhammer T. (2003). Biliary excretion of favopiridol and its glucuronides in the isolated perfused rat liver: Role of multidrug resistance protein 2 (Mrp2). Life Sci 73:2841-2854. (Pubitemid 37153358)
62. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U. (1999). Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173-179. (Pubitemid 29072068)
63. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U. (2000). Lactonization is the critical frst step in the disposition of the 50hydroxy-3-methylglutaryl-CoA reductase inhibitor atrorvastatin. Drug Metab Dispos 28:1369-1378.
64. Jones HM, Parrott N, Jorga K, Lavé T. (2006). A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542.
65. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. (2005). Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Efect of fbrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256. (Pubitemid 41433700)
66. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522. (Pubitemid 41017600)
67. Kanamitsu S, Ito K, Sugiyama Y. (2000). Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336-343. (Pubitemid 30225138)
68. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ. (2000). Efect of fuconazole on plasma fuvastatin and pravastatin concentrations. Eur J Clin Pharmacol 56:225-229. (Pubitemid 30456682)
69. Kantola T, Kivistö KT, Neuvonen PJ. (1998). Efect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ter 64:58-65.
70. Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB. (2006). Organic anion transporting polypeptide 1B1 activity classifed by SLCO1B1 genotype infuences atrasentan pharmacokinetics. Clin Pharmacol Ter 79: 186-196.
71. Keppler D, Arias IM. (1997). Hepatic canalicular membrane. Introduction: Transport across the hepatocyte canalicular membrane. FASEB J 11:15-18.
72. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. (2009). ABCG2 polymorphism markedly afects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ter 86:197-203.
73. Kimoto E, Chupka J, Xiao Y, Bi YA, Duignan DB. (2011). Characterization of digoxin uptake in sandwich-cultured human hepatocytes. Drug Metab Dispos 39:47-53.
74. Kindla J, Müller F, Mieth M, Fromm MF, König J. (2011). Infuence of non-steroidal anti-infammatory drugs on organic anion transporting polypeptide (OATP) 1B1-and OATP1B3-mediated drug transport. Drug Metab Dispos 39:1047-1053.
75. Kirby RS. (1998). Terazosin in benign prostatic hyperplasia: Efects on blood pressure in normotensive and hypertensive men. Br J Urol 82:373-379. (Pubitemid 28434610)
76. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG. (2010). Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 106:297-306.
77. König J, Cui Y, Nies AT, Keppler D. (2000). Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161-23168. (Pubitemid 30646210)
78. König J. (2010). Uptake transporters of the human OATP family: Molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Drug Transporters, Springer Berlin Heidelberg. 201: 1-28.
79. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. (1998). Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ter 286:1043-1050. (Pubitemid 29003502)
80. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. (2001). Plasma concentrations of active lovastatin acid are markedly increased by gemfbrozil but not by bezafbrate. Clin Pharmacol Ter 69:340-345. (Pubitemid 32477075)
81. Lam JL, Benet LZ. (2004). Hepatic microsome studies are insufcient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: Studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32:1311-1316. (Pubitemid 39410918)
82. Lam JL, Okochi H, Huang Y, Benet LZ. (2006a). In vitro and in vivo correlation of hepatic transporter efects on erythromycin metabolism: Characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336-1344. (Pubitemid 44079874)
83. Lam JL, Shugarts SB, Okochi H, Benet LZ. (2006b). Elucidating the efect of fnal-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ter 319:864-870.
84. Lau YY, Huang Y, Frassetto L, Benet LZ. (2007). efect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ter 81:194-204. (Pubitemid 46174816)
85. Li N, Nemirovskiy OV, Zhang Y, Yuan H, Mo J, Ji C, Zhang B, Brayman TG, Lepsy C, Heath TG, Lai Y. (2008). Absolute quantifcation of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal Biochem 380:211-222.
86. Liu X, LeCluyse EL, Brouwer KR, Lightfoot RM, Lee JI, Brouwer KL. (1999). Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ter 289:1592-1599. (Pubitemid 29246695)
87. Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS. (2006). Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: Evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600-1605. (Pubitemid 44285402)
88. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y. (2006). Efects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ter 79:427-439.
89. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. (2008). Investigation of the inhibitory efects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663-669. (Pubitemid 351468371)
90. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. (1997). Substrate specifcity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667-1677. (Pubitemid 27520039)
91. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. (2004). Te organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19:171-179.
92. Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, Kuhlmann J. (1997). Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ter 35:255-260. (Pubitemid 27268175)
93. Müller M, Jansen PL. (1997). Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285-G1303.
94. Mwinyi J, Johne A, Bauer S, Roots I, Gerlof T. (2004). Evidence for inverse efects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ter 75:415-421. (Pubitemid 38534562)
95. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T. (2006). OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 34:862-869.
96. Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ter 80:565-581. (Pubitemid 44908269)
97. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. (2003). Efects of gemfbrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: Potentially hazardous interaction between gemfbrozil and repaglinide. Diabetologia 46:347-351. (Pubitemid 36547589)
98. Niemi M, Schaefeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440. (Pubitemid 38971233)
99. Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm M F. (2005). Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602-604. (Pubitemid 40632253)
100. Niemi M, Pasanen MK, Neuvonen PJ. (2006). SLCO1B1 polymorphism and sex afect the pharmacokinetics of pravastatin but not fuvastatin. Clin Pharmacol Ter 80:356-366. (Pubitemid 44465886)
101. Niemi M. (2010). Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ter 87:130-133.
102. Niemi M, Pasanen MK, Neuvonen PJ. (2011). Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
103. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. (2003). Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ter 73:554-565. (Pubitemid 37249126)
104. Noé J, Portmann R, Brun ME, Funk C. (2007). Substrate-dependent drug-drug interactions between gemfbrozil, fuvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308-1314. (Pubitemid 47121771)
105. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. (2004). Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ter 308:438-445. (Pubitemid 38134202)
106. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. (2006). Glucuronidation converts gemfbrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab Dispos 34:191-197. (Pubitemid 43042661)
107. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U. (1997). Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ter 62:311-321. (Pubitemid 27417797)
108. Paine SW, Parker AJ, Gardiner P, Webborn PJ, Riley RJ. (2008). Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36:1365-1374. (Pubitemid 351929321)
109. Park JW, Siekmeier R, Merz M, Krell B, Harder S, März W, Seidel D, Schüler S, Gross W. (2002). Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ter 40:439-450.
110. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. (2006). SLCO1B1 polymorphism markedly afects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873-879. (Pubitemid 44772805)
111. Pasanen MK, Neuvonen PJ, Niemi M. (2008). Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19-33. (Pubitemid 351560529)
112. Petzinger E. (1994). Transport of organic anions in the liver. An update on bile acid, fatty acid, monocarboxylate, anionic amino acid, cholephilic organic anion, and anionic drug transport. Rev Physiol Biochem Pharmacol 123:47-211. (Pubitemid 2046669)
113. Pfeferkorn JA, Litchfeld J, Hutchings R, Cheng XM, Larsen SD, Auerbach B, Bush MR, Lee C, Erasga N, Bowles DM, Boyles DC, Lu G, Sekerke C, Askew V, Hanselman JC, Dillon L, Lin Z, Robertson A, Olsen K, Boustany C, Atkinson K, Goosen TC, Sahasrabudhe V, Chupka J, Duignan DB, Feng B, Scialis R, Kimoto E, Bi YA, Lai Y, El-Kattan A, Bakker-Arkema R, Barclay P, Kindt E, Le V, Mandema JW, Milad M, Tait BD, Kennedy R, Trivedi BK, Kowala M. (2011). Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution. Bioorg Med Chem Lett 21:2725-2731.
114. Poirier A, Funk C, Scherrmann JM, Lavé T. (2009). Mechanistic modeling of hepatic transport from cells to whole body: Application to napsagatran and fexofenadine. Mol Pharm 6:1716-1733.
115. Regazzi MB, Iacona I, Campana C, Gavazzi A, Viganò M, Perani G. (1994). Clinical efcacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 26:2644-2645. (Pubitemid 24329263)
116. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, Gavazzi A, Viganò M. (1993). Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25:2732-2734. (Pubitemid 23239614)
117. Rostami-Hodjegan A, Tucker GT. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148. (Pubitemid 46745341)
118. Sasabe H, Terasaki T, Tsuji A, Sugiyama Y. (1997). Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J Pharmacol Exp Ter 282:162-171. (Pubitemid 27425538)
119. Search Collaborative Group (2008). SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359:789-799.
120. Seithel A, Glaeser H, Fromm MF, König J. (2008). Te functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol 4:51-64. (Pubitemid 351234100)
121. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477-1481. (Pubitemid 41323995)
122. Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446. (Pubitemid 43363338)
123. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ter 304:610-616. (Pubitemid 36152336)
124. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y. (2003b). Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18:33-41.
125. Shitara Y, Hirano M, Sato H, Sugiyama Y. (2004). Gemfbrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfbrozil. J Pharmacol Exp Ter 311:228-236. (Pubitemid 39287802)
126. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. (2004). Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ter 76: 167-177. (Pubitemid 39013406)
127. Smith DA, Jones BC. (1992). Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44:2089-2098.
128. Smith DA, Jones BC, Walker DK. (1996). Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16:243-266. (Pubitemid 26146807)
129. Smith NF, Figg WD, Sparreboom A. (2005). Role of the liver-specifc transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 1:429-445.
130. Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859-865. (Pubitemid 46798596)
131. St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ, Stallmach T. (2002). Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 87: 1856-1863. (Pubitemid 34615280)
132. Sultanpur C, Satyanarayana S, Reddy N, Kumar K, Kumar S. (2010). Drug-drug Interaction between Pravastatin and Gemfbrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats. J Young Pharm 2:152-155.
133. Swift B, Pfeifer ND, Brouwer KL. (2010). Sandwich-cultured hepatocytes: An in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446-471.
134. Takahashi H, Kim RB, Perry PR, Wilkinson GR. (1997). Characterization of the hepatic canalicular membrane transport of a model oligopeptide: Ditekiren. J Pharmacol Exp Ter 281:297-303. (Pubitemid 27203081)
135. Tosco P Rolando B, Fruttero R, Henchoz Y, Martel S, Carrupt P-A, andandGasco A.(2008) Physicochemical profling of sartans: A detailed study of ioization constants and distribution coefcients. Helvetica Chimica Acta 91:2379-2398.
136. Treiber A, Schneiter R, Häusler S, Stieger B. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafl. Drug Metab Dispos 35:1400-1407. (Pubitemid 47121782)
137. van Giersbergen PL, Halabi A, Dingemanse J. (2002). Single-and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 53:589-595. (Pubitemid 34621784)
138. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. (2009a). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ter 328:652-662.
139. Watanabe T, Maeda K, Kondo T, Nakayama H, Horita S, Kusuhara H, Sugiyama Y. (2009b). Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab Dispos 37:1471-1479.
140. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA, Jonkman JH, Jones CR. (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ter 60:124-137. (Pubitemid 26348226)
141. Werner D, Werner U, Meybaum A, Schmidt B, Umbreen S, Grosch A, Lestin HG, Graf B, Zolk O, Fromm MF. (2008). Determinants of steady-state torasemide pharmacokinetics: Impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet 47:323-332. (Pubitemid 351508118)
142. White EP, Pimprale S, Yu Z, Ketty V, Bourgea J, Patten CJ, Crespi C and Xiao G. (2006) Cloning and characterization of cynomolgus monkey and rhesus monkey organic anion transporting poloypeptide 1B3 and comparison of their function with human OATP-1B3. AAPS Annual meeting and exposition.
143. Wienen W, Entzeroth M, van Meel JCA, Stangier J, Busch U, Ebher T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson, Gladigau V, Hauel NH. (2000) A review on telmisartan: A novel long-acting angiotensin II receptor antagonist. Cardiovascular Drug Rev 18:127-154.
144. Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classifcation system. Pharm Res 22:11-23. (Pubitemid 40558141)
145. Xiong H, Carr RA, Locke CS, Katz DA, Achari R, Doan TT, Wang P, Jankowski JR, Sleep DJ. (2007). Dual efects of rifampin on the pharmacokinetics of atrasentan. J Clin Pharmacol 47: 423-429. (Pubitemid 46465965)
146. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, Nakazawa H, Okano T, Adachi M, Schuetz JD, Adachi Y, Hu Z, Kusuhara H, Sugiyama Y. (2007). Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35:2166-2176. (Pubitemid 350146202)
147. Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y. (1993). Na(+)-independent multispecifc anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44. (Pubitemid 23055986)
148. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. (1996). Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 13:1559-1564. (Pubitemid 26356962)
149. Yamazaki M, Suzuki H, Sugiyama Y. (1996). Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497-513. (Pubitemid 26119682)
150. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl ML. (2002). Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ter 71:89-98. (Pubitemid 34124042)
151. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. (2006). Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247-1254.
152. Zhang L, Zhang Y, Huang SM. (2009). Scientifc and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: Challenges in predicting drug interactions. Mol Pharm 6:1766-1774.